Loading
A phase 1 trial of WTX-330 run by Werewolf Therapeutics, Inc., completed.
WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma is a phase 1 interventional study registered as NCT05678998 by Werewolf Therapeutics, Inc., with 25 participants enrolled, started 2022-12-06. Conditions recorded: Advanced or Metastatic Solid Tumors and Non-Hodgkin Lymphoma. Interventions recorded: WTX-330.
Shares WTX-330, Werewolf Therapeutics, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Werewolf Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Werewolf Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/